<DOC>
	<DOCNO>NCT00551525</DOCNO>
	<brief_summary>RATIONALE : Giving samarium Sm 153 lexidronam pentasodium 3-dimensional ( 3-D ) conformal radiation therapy intensity-modulated radiation therapy may keep prostate cancer grow patient rise prostate-specific antigen ( PSA ) level radical prostatectomy prostate cancer . PURPOSE : This phase II trial study well samarium Sm 153 lexidronam pentasodium 3-D conformal radiation therapy intensity-modulated radiation therapy work treat patient rise PSA level radical prostatectomy prostate cancer .</brief_summary>
	<brief_title>Samarium Sm 153 Lexidronam Pentasodium 3-Dimensional Conformal Radiation Therapy Intensity-Modulated Radiation Therapy Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess effectiveness samarium Sm 153 lexidronam pentasodium ( determined 30 % decline PSA level within 12 week ) follow either three-dimensional conformal radiation therapy intensity-modulated radiation therapy patient rise prostate-specific antigen level ( PSA ) radical prostatectomy prostate cancer . Secondary - To assess proportion patient complete protocol treatment . - To evaluate hematological toxicity 12 week . - To evaluate samarium Sm 153 lexidronam pentasodium-related adverse event 12 week . - To evaluate `` acute '' `` late '' radiation therapy-related event occur 24 week end radiation therapy . - To compare freedom progression rate 2 year predict Kattan Nomograms . OUTLINE : Patients receive samarium Sm 153 lexidronam pentasodium ( SM ) IV day 1 . Patients closely monitor prostate-specific antigen ( PSA ) level SM-associated toxicity 12 week . After 12 week , patient undergo either intensity-modulated radiation therapy 3-dimensional conformal radiation therapy 5 day week 7-8 week . Patients may receive hormonal therapy ( radiation therapy ) discretion physician . Treatment continue absence disease progression ( define PSA double time le 3 month ) , severe thrombocytopenia ( defined platelet count 25,000 cells/mm³ less ) , unacceptable toxicity . After completion study treatment , patient follow 3 month , 6 month , 12 month , every 6 month 2 year , annually thereafter .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Samarium ethylenediaminetetramethylenephosphonate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Inclusion criterion : Histologically proven diagnosis prostate cancer progress prior radical prostatectomy indicate one following : Postoperative prostatespecific antigen ( PSA ) rise 1.0 ng/mL Postoperative PSA rise 0.2 ng/mL surgical tumor Gleason score 9 10 Postoperative PSA rise 0.2 ng/ml nodal disease Stage IIIV disease ( T2 T4 , N0N1 ) No distant metastasis base follow minimum diagnostic work : History physical examination within past 8 week Bone scan negative bone metastasis within past 4 month Abdominal image negative metastasis within past 6 month Exclusion criterion : Biopsy evidence M1 disease Presence neuroendocrine feature prostate cancer specimen PATIENT CHARACTERISTICS : Inclusion criterion : Zubrod Performance Status 01 Absolute neutrophil count ( ANC ) ≥ 1,800 cells/mm³ Platelet count ≥ 100,000 cells/mm³ Hemoglobin ≥ 8.0 g/dL ( transfusion intervention achieve Hgb ≥ 8.0 g/dl permit ) Exclusion criterion : Prior invasive malignancy ( except nonmelanoma skin cancer ) unless disease free minimum 3 year Severe , active comorbidity , define follow : Unstable angina and/or congestive heart failure require hospitalization within last 6 month Transmural myocardial infarction within last 6 month Acute bacterial fungal infection require intravenous antibiotic time registration Hepatic insufficiency result clinical jaundice and/or coagulation defect ( laboratory test liver function coagulation parameter , however , required entry protocol ) Renal failure ( laboratory test renal function , however , required entry protocol ) AIDS base upon current Centers Disease Control ( CDC ) definition ( HIV test require ) PRIOR CONCURRENT THERAPY : No prior systemic chemotherapy study cancer Prior chemotherapy different cancer permit No hormonal therapy initiate within last 3 month No prior radiotherapy pelvic region would result overlap radiotherapy field</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>